Soleno Therapeutics (SLNO) Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SLNO Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Soleno Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$50.45 |
| 52 Week High | US$90.32 |
| 52 Week Low | US$41.50 |
| Beta | -3.19 |
| 1 Month Change | -24.88% |
| 3 Month Change | -24.95% |
| 1 Year Change | 0.90% |
| 3 Year Change | 5,095.67% |
| 5 Year Change | 77.02% |
| Change since IPO | -83.23% |
Recent News & Updates
Recent updates
Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory
Mar 21We're Hopeful That Soleno Therapeutics (NASDAQ:SLNO) Will Use Its Cash Wisely
Feb 26
Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth
Nov 08Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments
Oct 10We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn
Mar 08Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation
Sep 20Soleno sheds 13% as 1-for-15 reverse stock split takes effect
Aug 26Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky
Aug 12Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment
Jul 20Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely
May 10We're A Little Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Rate
Jan 24Shareholder Returns
| SLNO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.9% | 3.1% | 2.9% |
| 1Y | 0.9% | 17.9% | 12.5% |
Return vs Industry: SLNO underperformed the US Biotechs industry which returned 17.9% over the past year.
Return vs Market: SLNO underperformed the US Market which returned 12.5% over the past year.
Price Volatility
| SLNO volatility | |
|---|---|
| SLNO Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SLNO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SLNO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 152 | Anish Bhatnagar | soleno.life |
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. Fundamentals Summary
| SLNO fundamental statistics | |
|---|---|
| Market cap | US$2.71b |
| Earnings (TTM) | -US$78.45m |
| Revenue (TTM) | US$98.68m |
Is SLNO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLNO income statement (TTM) | |
|---|---|
| Revenue | US$98.68m |
| Cost of Revenue | US$1.84m |
| Gross Profit | US$96.84m |
| Other Expenses | US$175.29m |
| Earnings | -US$78.45m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.46 |
| Gross Margin | 98.14% |
| Net Profit Margin | -79.50% |
| Debt/Equity Ratio | 10.1% |
How did SLNO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/01 08:27 |
| End of Day Share Price | 2025/11/28 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Soleno Therapeutics, Inc. is covered by 17 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| François Brisebois | Craig-Hallum Capital Group LLC |